Unibest

Pharmaceutical intermediates

Lazertinib Mesylate Intermediates

6 pharmaceutical intermediates for Lazertinib Mesylate. Indication: Non-Small Cell Lung Cancer.

提交项目All intermediates

About Lazertinib Mesylate

Originator
Oscotec Inc; Janssen Biotech Inc
Indication
Non-Small Cell Lung Cancer
Approved Date
08/19/2024
NCE Patent
08/19/2029
DS/DP
10/13/2035

Available intermediates

6 intermediates currently listed for Lazertinib Mesylate. Request specifications, documentation or a quotation for any item below.

Lazertinib Mesylate intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
3-phenyl-1H-pyrazole-4-carbaldehyde26033-20-5//
4-Chloro-2-(methylsulfonyl)pyrimidine97229-11-3//
4-chloro-N-(2-methoxy-4-morpholino-5-nitrophenyl)pyrimidin-2-amine2270944-70-0//
1-(2-((2-methoxy-4-morpholino-5-nitrophenyl)amino)pyrimidin-4-yl)-3-phenyl-1H-pyrazole-4-carbaldehyde1903010-39-8//
4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)-N-(2-methoxy-4-morpholino-5-nitrophenyl)pyrimidin-2-amine1903009-55-1//
N1-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidin-2-yl)-6-methoxy-4-morpholinobenzene-1,3-diamine1903009-56-2//

Other programs under L

(LCZ696)LanifibranorLapatinibLarotrectinibLasmiditanLemborexantLenacapavir sodiumLenalidomide

Building toward Lazertinib Mesylate?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →